240 related articles for article (PubMed ID: 9445190)
21. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
[TBL] [Abstract][Full Text] [Related]
22. Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas.
Chamberlain MC
J Neurooncol; 2002 Sep; 59(2):157-63. PubMed ID: 12241109
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer.
Machida S; Ohwada M; Fujiwara H; Konno R; Takano M; Kita T; Kikuchi Y; Komiyama S; Mikami M; Suzuki M
Oncology; 2003; 65(2):102-7. PubMed ID: 12931014
[TBL] [Abstract][Full Text] [Related]
24. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
[TBL] [Abstract][Full Text] [Related]
25. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
[TBL] [Abstract][Full Text] [Related]
26. [A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers].
Takeuchi S; Dobashi K; Fujimoto S; Tanaka K; Suzuki M; Terashima Y; Hasumi K; Akiya K; Negishi Y; Tamaya T
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1681-9. PubMed ID: 1872624
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer.
Sugiyama T; Yakushiji M; Noda K; Ikeda M; Kudoh R; Yajima A; Tomoda Y; Terashima Y; Takeuchi S; Hiura M; Saji F; Takahashi T; Umesaki N; Sato S; Hatae M; Ohashi Y
Oncology; 2000; 58(1):31-7. PubMed ID: 10644938
[TBL] [Abstract][Full Text] [Related]
28. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.
de Forni M; Bugat R; Chabot GG; Culine S; Extra JM; Gouyette A; Madelaine I; Marty ME; Mathieu-Boué A
Cancer Res; 1994 Aug; 54(16):4347-54. PubMed ID: 8044782
[TBL] [Abstract][Full Text] [Related]
29. [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].
Futatsuki K; Wakui A; Nakao I; Sakata Y; Kambe M; Shimada Y; Yoshino M; Taguchi T; Ogawa N
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1033-8. PubMed ID: 8210254
[TBL] [Abstract][Full Text] [Related]
30. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
[TBL] [Abstract][Full Text] [Related]
31. Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer.
Tsuda H; Hashiguchi Y; Nishimura S; Miyama M; Nakata S; Kawamura N; Negoro S
Br J Cancer; 2004 Sep; 91(6):1032-7. PubMed ID: 15292935
[TBL] [Abstract][Full Text] [Related]
32. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
33. Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Muggia FM; Blessing JA; McGehee R; Monk BJ
Gynecol Oncol; 2004 Aug; 94(2):483-7. PubMed ID: 15297192
[TBL] [Abstract][Full Text] [Related]
34. [A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer].
Taguchi T; Tominaga T; Ogawa M; Ishida T; Morimoto K; Ogawa N
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1017-24. PubMed ID: 8210251
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy.
García-Girón C; García Palomo A; Alonso López C; León Carbonero A; Méndez Ureña M; Adróver Cebrián E; Barceló Galíndez R; Arroyo Yustos M; Alvarez Gallego J
Clin Transl Oncol; 2005 Jul; 7(6):244-9. PubMed ID: 16131447
[TBL] [Abstract][Full Text] [Related]
36. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
[TBL] [Abstract][Full Text] [Related]
37. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme.
Chamberlain MC
J Neurooncol; 2002 Jan; 56(2):183-8. PubMed ID: 11995820
[TBL] [Abstract][Full Text] [Related]
38. [Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies].
Ota K; Ohno R; Shirakawa S; Masaoka T; Okada K; Ohashi Y; Taguchi T
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1047-55. PubMed ID: 8210256
[TBL] [Abstract][Full Text] [Related]
39. [Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Couteau C; Yakendji K; Terret C; Goncalves E; Armand JP
Bull Cancer; 1996 Jan; 83(1):3-10. PubMed ID: 8672854
[TBL] [Abstract][Full Text] [Related]
40. Intermittent, repetitive administrations of irinotecan (CPT-11) reduces its side-effects.
Fujii H; Koshiyama M; Konishi M; Yoshida M; Tauchi K
Cancer Detect Prev; 2002; 26(3):210-2. PubMed ID: 12269768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]